Liraglutide vs. lixisenatide in obese type 2 diabetes mellitus patients: What effect should we expect in routine clinical practice?

•Comparative effectiveness and safety results of GLP-1 receptor agonists (Lira vs. Lixi) in routine clinical practice.•Additional Liraglutide effects beyond glycated haemoglobin registered through continuous glucose monitoring system.•Antidiabetic treatment modifications when adding GLP-1 receptor a...

Full description

Saved in:
Bibliographic Details
Published in:Primary care diabetes 2020-02, Vol.14 (1), p.68-74
Main Authors: Moreno-Fernandez, Jesus, Garcia-Seco, Jose Alberto, Seco Segura, Angela Maria, Garcia-Seco, Fernando, Rozas Moreno, Pedro Jesus, Aguirre Sanchez-Covisa, Miguel
Format: Article
Language:English
Subjects:
Adult
Aged
Biomarkers - blood
Blood Glucose - drug effects
Blood Glucose - metabolism
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - diagnosis
Diabetes Mellitus, Type 2 - drug therapy
Female
GLP-1 receptor agonists
Glucagon-Like Peptide-1 Receptor - agonists
Glycated Hemoglobin A - metabolism
Humans
Hypoglycemic Agents - adverse effects
Hypoglycemic Agents - therapeutic use
Liraglutide
Liraglutide - adverse effects
Liraglutide - therapeutic use
Lixisenatide
Male
Middle Aged
Obesity
Obesity - diagnosis
Obesity - drug therapy
Obesity - physiopathology
Peptides - adverse effects
Peptides - therapeutic use
Prospective Studies
Routine clinical practice
Spain
Time Factors
Treatment Outcome
Type 2 diabetes mellitus
Weight Loss - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Comparative effectiveness and safety results of GLP-1 receptor agonists (Lira vs. Lixi) in routine clinical practice.•Additional Liraglutide effects beyond glycated haemoglobin registered through continuous glucose monitoring system.•Antidiabetic treatment modifications when adding GLP-1 receptor agonists in a real-world scenario. Liraglutide and lixisenatide improved glycemic control, weight and cardiovascular risk factors (CVRF) in type 2 diabetes mellitus (T2DM) patients. Our objective was to analyze clinical efficacy and safety differences in routine clinical practice. A 24-week prospective observational study to compare the effect of liraglutide versus lixisenatide in obese T2DM patients in routine clinical practice. The main objective was to analyze between-group glycosylated hemoglobin (HbA1c) differences at the end of the study. Secondary objectives included differences in body weight, other CVRF, changes in medication, side effects, satisfaction and safety. A total of 100 patients (50 liraglutide, 50 lixisenatide) were included. Both groups experienced a decrease in HbA1c values (liraglutide, −1.4%, CI 95% −2, −0.8, P 
ISSN:1751-9918
1878-0210
DOI:10.1016/j.pcd.2019.05.006